Moonlight AI raises €2.8M Seed to turn routine blood imaging into genomic insights
What's the deal? Moonlight AIDealroom has a profile for this one. Try Dealroom →, a Swiss healthtech startup, has closed a €2.8M seed round to advance its AI software that extracts genomic insights from routine blood and cytology images. The round was co-led by Lotus One InvestmentDealroom has a profile for this one. Try Dealroom → (Singapore), VP Venture PartnersDealroom has a profile for this one. Try Dealroom → (Switzerland), and MEDIN FundDealroom has a profile for this one. Try Dealroom → (Tunisia), with additional backing from N&V CapitalDealroom has a profile for this one. Try Dealroom → and existing investor QAI VenturesDealroom has a profile for this one. Try Dealroom →.
Founded in 2022 by Christian RuizDealroom has a profile for this one. Try Dealroom → (chief executive officer), Nicole H. RomanoDealroom has a profile for this one. Try Dealroom → (chief technology officer), and Dr Stefan HabringerDealroom has a profile for this one. Try Dealroom → (chief medical officer), Moonlight AI uses computer vision to detect genomic biomarkers directly from standard lab imaging — no costly molecular testing required upfront.
Why now? Cancer diagnostics increasingly depend on genomic data, but molecular testing remains expensive and slow. Moonlight AI claims to have built the first proprietary data library connecting whole slide imaging of cytopathology samples with high-quality genomic data — a foundation that positions it to offer faster, cheaper diagnostic triage.
The funds will go toward expanding that data library, growing the team, and developing diagnostic solutions for myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukaemia. The company also plans to accelerate its path to commercialisation and regulatory approval.
What could go wrong? Medical AI faces a long road from prototype to clinical use. Regulatory approval — especially across multiple jurisdictions — is notoriously slow and uncertain. The company must prove its software meets clinical-grade accuracy standards before hospitals and labs will adopt it.
There's also the data challenge. Building a proprietary imaging-genomics dataset is capital-intensive, and €2.8M is a modest war chest for a startup tackling regulated healthcare markets.
The signal: Moonlight AI's seed round draws from an unusually geographically dispersed syndicate — spanning Singapore, Switzerland, Tunisia, and Liechtenstein — underscoring growing cross-continental investor appetite for AI-driven diagnostics outside the traditional US and UK venture corridors. Dealroom lists the company at the early growth stage, suggesting its proprietary imaging-genomics data library has already attracted enough clinical traction to move beyond pure research. With molecular testing still a bottleneck in cancer care, startups that can triage genomic insights from routine lab imaging could unlock significant value at the point of diagnosis.
Read more: The SaaS News
Image: Margherita / Wikimedia Commons (CC BY 4.0)
